Key PointsQuestionWhat is the relative cardiovascular (CV) efficacy and safety of dapagliflozin according to the baseline estimated glomerular filtration rate and urinary albumin to creatinine ratio in patients with type 2 diabetes? FindingsIn this secondary analysis of 17 160 participants included in the DECLARE-TIMI 58 trial, the effect of dapagliflozin (vs placebo) on the relative risk of a composite of CV death and hospitalization for heart failure (HHF) and of major adverse cardiovascular events was similar. However, the absolute risk reduction of CV death and HHF was significantly larger for dapagliflozin-treated patients who had more markers of chronic kidney disease. MeaningIn this study, the effect of dapagliflozin on the relative risk for CV events was consistent across kidney function and albuminuria status, with the greatest absolute benefit for the composite of CV death or HHF observed among patients with both reduced estimated glomerular filtration rate and albuminuria.
JAMA Cardiology – American Medical Association
Published: Jul 14, 2021